The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.

End-stage renal disease (ESRD) typically is associated with severe anemia. The major contributor to the anemia appears to be the absolute or relative deficiency of erythropoietin (EPO) production by the kidney. A series of clinical trials have been conducted in the United States using recombinant human EPO (rh EPO) to treat anemic patients with ESRD.

[Oncogen infectious nucleoprotein and herpes virus hominis type 2 in stages of cervical cancer. Investigatious by indirect immunofluorescens].

Using HVH 2 antisera of rabbit (titre 1:256, dilution 1:10), antologous serum of cervix carcinoma patients (dilution 1:1 to 1:5) and allogenic serum of cervix carcinoma patients without HVH 2 antibodies (dilution 1:1 to 1:5), tumour material obtained from various cancerization stages of cervix carcinoma in 50 cases was incubated following trypsination to single cells with fluoresceine isothiocyanate labelled anti-human globulin and anti-rabbit globulin. Apart from HVH antigens significantly differing in quantity from one stage to the other as detected by immune fluorescence methods, a perinuclear distinct antigen, unrelated to HVH antigens, has also been demonstrated. The last mentioned one might be a specific tumour antigen or an embryonic antigen.